13F Data
13F filer · CIK 1583977

Cormorant Asset Management, LP

BOSTON, MA · filing since Q4 2013 · last filing Aug 14, 2026
Reported value
$2.0B
$-39.6M vs prior
Positions
50
New / sold out
13 / 10
Added / reduced
4 / 28
Turnover
14.2%
buys $279.6M · sells $558.1M
Top-10 weight
59.2%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewPARABILIS MEDICINES INC+4,615,612–+$126.3M
NewCLIMB BIO INC+2,106,000–+$27.5M
NewSPYRE THERAPEUTICS INC+225,000–+$20.0M
NewDEFINIUM THERAPEUTICS INC+400,000–+$18.8M
NewASCENDIS PHARMA A/S+50,000–+$13.3M
AddedBIOHAVEN LTD+850,000+48.3%+$12.6M
AddedADLAI NORTYE LTD+1,080,372+37.3%+$12.4M
NewKAILERA THERAPEUTICS INC+550,000–+$12.1M
NewENLIVEN THERAPEUTICS INC+150,000–+$7.6M
NewIBIO INC+3,570,000–+$6.2M
7 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
ReducedPRAXIS PRECISION MEDICINES I-245,500-27.7%$-82.2M
Sold outCENTESSA PHARMACEUTICALS PLC-1,050,000-100.0%$-41.7M
ReducedMBX BIOSCIENCES INC-570,000-50.9%$-31.5M
ReducedEDGEWISE THERAPEUTICS INC-750,000-23.0%$-30.5M
ReducedMOONLAKE IMMUNOTHERAPEUTICS-1,275,000-28.5%$-24.8M
Sold outMAZE THERAPEUTICS INC-750,000-100.0%$-22.4M
ReducedBRIDGEBIO PHARMA INC-300,000-35.3%$-22.3M
ReducedOLEMA PHARMACEUTICALS INC-1,750,000-44.9%$-21.9M
Sold outASCENDIS PHARMA A/S-95,000-100.0%$-21.7M
ReducedDIANTHUS THERAPEUTICS INC-200,000-21.1%$-19.5M
28 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2013: $344.6MQ1 2014: $434.9MQ2 2014: $377.4MQ3 2014: $486.2MQ4 2014: $648.5MQ1 2015: $647.1MQ2 2015: $752.2MQ3 2015: $626.1MQ4 2015: $835.9MQ1 2016: $663.8MQ2 2016: $705.2MQ3 2016: $906.8MQ4 2016: $741.8MQ1 2017: $688.7MQ2 2017: $603.3MQ3 2017: $566.4MQ4 2017: $955.3MQ1 2018: $1.3BQ2 2018: $1.4BQ3 2018: $1.5BQ4 2018: $1.2BQ1 2019: $1.5BQ2 2019: $1.7BQ3 2019: $1.6BQ4 2019: $2.5BQ1 2020: $2.2BQ2 2020: $2.6BQ3 2020: $2.6BQ4 2020: $4.2BQ1 2021: $4.5BQ2 2021: $2.9BQ3 2021: $2.5BQ4 2021: $1.7BQ1 2022: $1.3BQ2 2022: $1.3BQ3 2022: $1.4BQ4 2022: $1.5BQ1 2023: $1.5BQ2 2023: $1.8BQ3 2023: $1.7BQ4 2023: $2.1BQ1 2024: $2.3BQ2 2024: $1.7BQ3 2024: $1.9BQ4 2024: $1.8BQ1 2025: $1.3BQ2 2025: $1.3BQ3 2025: $1.4BQ4 2025: $2.2BQ1 2026: $2.0BQ2 2026: $2.0B
Q4 2013Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1PRAXIS PRECISION MEDICINES ICOM NEW640,000$214.3M10.98%
2BRIDGEBIO ONCOLOGY THERAPEUTCOM NEW17,878,594$136.2M6.98%
3PARABILIS MEDICINES INCCOM4,615,612$126.3M6.47%
4RAPPORT THERAPEUTICS INCCOM2,657,521$110.7M5.67%
5ERASCA INCCOM6,000,000$109.9M5.63%
6EDGEWISE THERAPEUTICS INCCOM2,510,000$102.0M5.23%
7EYEPOINT INCCOM NEW7,000,000$100.1M5.13%
8ALUMIS INCCOM3,285,596$92.5M4.74%
9ABIVAX SASPONSORED ADS675,000$90.0M4.61%
10DIANTHUS THERAPEUTICS INCCOM750,000$73.1M3.75%
40 more rows. Subscribe for $29/month to see every row, download the data and use the API.